The National Institute for Health and Care Excellence has issued preliminary guidelines recommending that the treatment be funded by the Cancer Drug Fund, giving hundreds of patients in England the chance to be among the first in Europe to access the drug.
Around 560 people per year with locally advanced or metastatic CSCC in adults, where curative surgery or curative radiotherapy is not appropriate, are eligible for treatment with Libtayo.
CSCC accounts for 20% of skin cancers and 23% of non-melanoma skin cancers. Although death is rare, the median overall survival rate of metastatic CSCC is poor at less than two years.
While there is significant uncertainty around the evidence for Libtayo, the committee noted that the overall response rates reported in the trials are “very promising”…